Carcinoembryonic antigen in patients with carcinoma of the lung.
D000230:Adenocarcinoma / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis*; D000970:Antineoplastic Agents / Q000494:pharmacology; D001219:Aspartate Aminotransferases / Q000097:blood; D001344:Autopsy; D002272:Carcinoembryonic Antigen / Q000032:analysis; D018288:Carcinoma, Small Cell / Q000276:immunology / Q000473:pathology; D003510:Cyclohexanes / Q000494:pharmacology; D004123:Dimethylamines / Q000494:pharmacology; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000494:pharmacology; D010178:Pancoast Syndrome / Q000276:immunology; D011863:Radioimmunoassay; D013997:Time Factors; D014227:Triazines / Q000494:pharmacology; D014750:Vincristine / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D003510:Cyclohexanes; D004123:Dimethylamines; D009607:Nitrosourea Compounds; D014227:Triazines; D014750:Vincristine; D001219:Aspartate Aminotransferases